Navigation Links
CV Therapeutics' Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36
Date:11/6/2007

- Data confirms safety and HbA1c reductions seen in ischemic patients with

diabetes in earlier clinical trials -

ORLANDO, Fla., Nov. 6 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that data from a prospectively identified analysis of 2,220 diabetic patients from the MERLIN TIMI-36 study showed that Ranexa(R) (ranolazine extended-release tablets) significantly reduced hemoglobin A1c (HbA1c), increased the number of patients achieving the clinical HbA1c treatment target of 7.0 percent or less and reduced the incidence of newly increased HbA1c in patients without diabetes at baseline.

The findings were presented today at the American Heart Association Scientific Sessions in Orlando, Florida by Dr. David Morrow of the TIMI Study Group.

In patients with diabetes treated with Ranexa in the study, at four months HbA1c had declined approximately 0.7 percentage points, from a starting mean baseline of 7.5 to 6.8 percent, and 0.43 percentage points compared to placebo (p<0.001). Patients taking Ranexa were significantly more likely (p<0.001) to achieve the HbA1c treatment target of less than 7.0 percent, with 59 percent of diabetic patients on Ranexa achieving this target at four months.

Patients without diabetes at baseline who received Ranexa had a 32 percent reduction (p=0.003) in their risk of newly diagnosed hyperglycemia (as defined by having an HbA1c of greater than 6.0 percent or a new fasting glucose of more than 110mg/dL). Worsening hyperglycemia (defined as greater than a one percent increase in HbA1c) was 37 percent less likely (p<0.001) in the Ranexa treated group and no increased hypoglycemia or weight gain were observed in Ranexa patient
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014 Endo International plc (NASDAQ: ... quarter 2014 revenues of $719 million, an increase of ... $712 million. Endo reported net income of $21 million ... of $35 million in the second quarter of 2013.  ... net income for the three months ended June 30, 2014 ...
(Date:7/31/2014)... Auxilium Pharmaceuticals, Inc. (NASDAQ: ... today announced that the Company will receive a ... Asahi Kasei Pharma Corporation (Asahi Kasei). The payment ... a regulatory application to the Japanese Pharmaceutical and ... (collagenase clostridium histolyticum) for the treatment of Dupuytren,s ...
(Date:7/30/2014)... Advanced Photonix ® (NYSE MKT: API) will ... results on Monday, August 11, 2014. A press release announcing ... the market and the Company will host a live audio ... on the same day. Participating in the call ... Rob Risser (COO and Director), and Jeff Anderson ...
Breaking Medicine Technology:Endo Reports Second Quarter Financial Results 2Endo Reports Second Quarter Financial Results 3Endo Reports Second Quarter Financial Results 4Endo Reports Second Quarter Financial Results 5Endo Reports Second Quarter Financial Results 6Endo Reports Second Quarter Financial Results 7Endo Reports Second Quarter Financial Results 8Endo Reports Second Quarter Financial Results 9Endo Reports Second Quarter Financial Results 10Endo Reports Second Quarter Financial Results 11Endo Reports Second Quarter Financial Results 12Endo Reports Second Quarter Financial Results 13Endo Reports Second Quarter Financial Results 14Endo Reports Second Quarter Financial Results 15Endo Reports Second Quarter Financial Results 16Endo Reports Second Quarter Financial Results 17Endo Reports Second Quarter Financial Results 18Endo Reports Second Quarter Financial Results 19Endo Reports Second Quarter Financial Results 20Endo Reports Second Quarter Financial Results 21Endo Reports Second Quarter Financial Results 22Endo Reports Second Quarter Financial Results 23Endo Reports Second Quarter Financial Results 24Endo Reports Second Quarter Financial Results 25Endo Reports Second Quarter Financial Results 26Endo Reports Second Quarter Financial Results 27Endo Reports Second Quarter Financial Results 28Endo Reports Second Quarter Financial Results 29Endo Reports Second Quarter Financial Results 30Endo Reports Second Quarter Financial Results 31Endo Reports Second Quarter Financial Results 32Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 2Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 3Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 4Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 5
... COLLEGEVILLE, Pa., and TARRYTOWN, N.Y., May 22 ... ), and Progenics,Pharmaceuticals, Inc. (Nasdaq: PGNX ), ... with investigational oral and,intravenous formulations of RELISTOR(TM) (methylnaltrexone ... phase 2 trial, evaluated the effects of,an oral ...
... LAS VEGAS, May 22 CardioVascular,BioTherapeutics, Inc. (OTC Bulletin ... Christopher Moore to be the sponsor and general,partner of ... of,$1 million and up to $10 million of the ... am extremely impressed with CVBT,s wound healing drug, which ...
Cached Medicine Technology:Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 2Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 3Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 4Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 5Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 6Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations 7Dr. Christopher Moore to Form ProDerm LP to Fund CVBT Wound Healing Trial 2Dr. Christopher Moore to Form ProDerm LP to Fund CVBT Wound Healing Trial 3
(Date:7/31/2014)... (PRWEB) July 31, 2014 Web Programming ... ISO 9001:2008 certified internet marketing firm, has recently launched ... to make this service affordable for everyone, the company ... the service. , Web Programming Services has tailored ... world of brochure designing and likely expectations of the ...
(Date:7/31/2014)... -- Recovery time after surgery may be reduced for ... to a new study. The study,s Irish researchers ... response, reducing the amount of time surgical patients, wounds ... true among people who tend to have healing complications. ... prescribed medications in the world. While they are typically ...
(Date:7/31/2014)... July 31, 2014 Ethane Web ... has introduced a new service named ‘Java Development’. ... Web Technologies has designed the service after doing ... and Java Development service being provided by other ... a confidence to promise outstanding Java Development service. ...
(Date:7/31/2014)... a unique protein that has the unusual property of destroying ... therefore be continually recreated and is no stable protein. The ... of coagulated blood. If you get a blood clot, it ... accumulated in a blood vessel, and therefore PAI-1 is extremely ... for helping people with a blood clot or other blood ...
(Date:7/31/2014)... Healthinsurancefacts.org has released a new blog post ... comparing quotes. , In order to find affordable ... quotes. They can do this by visiting an insurance ... , Clients should do proper research when looking for ... and each of them can be advantageous in the ...
Breaking Medicine News(10 mins):Health News:Web Programming Services Introduces Affordable Brochure Designing Service 2Health News:Cholesterol Drugs May Speed Healing After Surgery 2Health News:Ethane Web Technologies Announces Java Development Service at Pocket Friendly Cost 2Health News:Breakthrough in understanding of important blood protein 2Health News:Breakthrough in understanding of important blood protein 3Health News:Comparing Health Insurance Quotes Can Help Clients Find Affordable Plans 2
... Weight Control Centers in Baltimore ... ... MED ) today announced that Medifast Franchise Systems has sold its,first franchise ... four Medifast Weight Control Centers in the Greater,Baltimore Metropolitan Area., The ...
... ocean and coastal environment is intimately linked to our health. ... Our beaches and coastal waters are increasingly contaminated. Yet there ... natural products and seafood benefits our oceans hold. ... says NOAA,s Juli Trtanj who serves as head of the ...
... Old London(R) Challenges Americans to Get Fit and Live a Healthier ... Lifestyle in ... Food Company, is launching a multi-faceted campaign aimed at,helping women renew their commitment ... feeling women get when they,are able to fit into an old pair of ...
... Management Services Corporation,(ADAMS) announced today that they ... Hospitals in Cleveland, Ohio with a target,completion ... hundred million,dollars will allow University Hospitals to ... also allowing them to provide further,research capabilities ...
... cutting-edge research with renowned clinics to,care for North ... WORTH, Texas, Feb. 18 The University of,North ... The Center for,Cancer and Blood Disorders [ http://www.texascancercare.com/ ... and Blood Disorders. The new,Institute,s goal is to ...
... ST. PAUL, Minn., Feb. 18 Regions Hospital,this week ... a first of,its kind in the region -- with ... unit will work a seven-day-on/seven-day-off schedule,providing improved continuity and ... model involves psychiatrists who will provide care for,patients once ...
Cached Medicine News:Health News:Medifast Franchise Systems Sells First Territory in Baltimore 2Health News:Medifast Franchise Systems Sells First Territory in Baltimore 3Health News:Oceans, coasts and your health: Reducing risks and reaping rewards 2Health News:Old London Launches Skinny Jeans Contest 2Health News:Old London Launches Skinny Jeans Contest 3Health News:Old London Launches Skinny Jeans Contest 4Health News:ADAMS Performs Management Services for University Hospitals' $600 Million Expansion/Renovation Program in Cleveland, OH 2Health News:UNT Health Science Center and The Center for Cancer and Blood Disorders Collaborate on New Institute for Cancer and Blood Disorders 2Health News:UNT Health Science Center and The Center for Cancer and Blood Disorders Collaborate on New Institute for Cancer and Blood Disorders 3Health News:Regions Hospital to Open New Inpatient Behavioral Health Unit 2
The AGC Revision Knee, extends the AGC Family to include implants for severe primary knees or revision. Provides rotational freedom of +/- 2 and varus/valgus freedom of +/- 1.5....
The Performance Knee System is a wide and easy to use system that offers enough options to cover any indication for primary and revision knee surgery, and all this with extensive intraoperative flexi...
The NexGen CR femoral component is intended for patients who, in the physician's judgement, have good bone stock and whose ligaments provide adequate mediolateral, anteroposterior, and varus/valgus s...
Cruciate retaining, posterior stabilized and constrained components....
Medicine Products: